Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences
MJH Life Sciences

SUBSCRIBE: Print / eNewsletter

TRC105 Gets Orphan Drug Status for Soft-Tissue Sarcoma

  • Dave Levitan
February 4, 2016
  • Sarcoma
A phase III trial will test TRC105 in angiosarcoma patients

The US Food and Drug Administration (FDA) has granted orphan drug designation for the novel agent known as TRC105, in development by Tracon Pharmaceuticals for the treatment of soft-tissue sarcoma.

Orphan drug status can grant the company tax credits and a reduction in certain fees associated with drug development and approval, in an effort to aid the development of agents created to address diseases affecting fewer than 200,000 people in the United States. About 13,000 new cases of soft-tissue sarcoma are diagnosed each year.

TRC105 is a novel antibody to endoglin, a protein that is overexpressed in endothelial cells and that is essential for angiogenesis.

“Orphan drug designation for TRC105 underscores the high level of unmet medical need in patients with soft-tissue sarcomas and validates our commitment to developing TRC105 in a variety of orphan drug indications,” said Charles Theuer, MD, PhD, the CEO of Tracon, in a press release. “We are highly encouraged by the clinical data reported to date from the phase Ib/II trial of TRC105 in sarcoma patients, especially in patients with angiosarcoma. We look forward to the availability of complete results from the phase II portion of the sarcoma trial and initiating a pivotal phase III trial in patients with angiosarcoma in 2016.”

The phase Ib/II trial has an estimated enrollment of 94 patients, with an estimated completion date of December 2016. It is testing TRC105 in combination with pazopanib for patients with unresectable soft-tissue sarcoma. The company also has ongoing clinical trials of the drug in advanced renal cell carcinoma, hepatocellular carcinoma, non–squamous cell lung cancer, and breast cancer.

Though sarcoma patients still represent an underserved population, there has been some recent progress in the field. In January, the FDA approved eribulin for the treatment of unresectable, metastatic liposarcoma. It was the first sarcoma agent to show a significant improvement in survival time.

The agency also approved trabectedin for the treatment of liposarcoma and leiomyosarcoma in October 2015, and granted orphan drug status to GPX-150, an analog of doxorubicin in testing for patients with soft-tissue sarcoma, in January of this year.

Related Articles

  • RNA Sequencing Shows Epigenetics Behind Pediatric Cancer
  • A 51-Year-Old Male With Abdominal Distention, Pain, and A Retroperitoneal Mass
  • New Hope for Advanced Sarcomas
  • Honing in on Subtypes to Guide More Individualized Treatment of Soft Tissue Sarcoma
  • For Advanced Sarcoma, Adding Lymphodepletion to HER2-Targeted CAR T-Cell Therapy Excites

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Breast Cancer
  • Acute Myeloid Leukemia
  • HER2-Positive Breast Cancer
  • Videos Breast Cancer
  • Follicular Lymphoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

ONCOLOGY Vol 33 No 11
Nov 21, 2019 Vol 33 No 11
Subscribe
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".